AGTC News and Press, Applied Genetic Technologies Corporation From 10/24/22

Applied Genetic Technologies ( NASDAQ: AGTC ) has entered into a definitive pact pursuant to which a newly established portfolio company of Syncona Limited to acquire former, through a tender offer, for ~$23.5M ($0.34 per share) in cash plus potential future aggregate cash...

Upfront consideration in cash of $0.34 per share representing a premium of approximately 42% over AGTC’s closing stock price on October 21, 2022 Total consideration of up to $1.07, including up to $0.73 per CVR, representing a premium of up to approximately 344% over AGTC...

Applied Genetic Technologies ( NASDAQ: AGTC ) said the U.S. Food and Drug Administration had provided favorable feedback on the current Good Manufacturing Practice (cGMP) design of AGTC’s manufacturing facility. The facility will support AGTC’s pipeline, ...

— FDA feedback marks a key milestone in the construction of the facility expected to support AGTC’s pipeline, including the late-stage development and potential commercialization of AGTC’s X-Linked Retinitis Pigmentosa (XLRP) and Achromatopsia B3 (ACHMB3) programs &#x...

Applied Genetic Technologies ( NASDAQ: AGTC ) stock slumped more than 50% Wednesday after the biotech firm priced a $10M underwritten public offering . AGTC fell as much as 54.1% to 38.94 cents per share before partly recovering to trade at 39.26 cents shortly before 3:30 ...

Applied Genetic Technologies ( NASDAQ: AGTC ) stock slumps 45% premarket after the firm prices an underwritten public offering of 16.67M common stock units and accompanying warrants to purchase up to 16.67M shares of common stock at a combined public offeri...

GAINESVILLE, Fla., and CAMBRIDGE, Mass., July 12, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (“AGTC” or the “Company”) (Nasdaq: AGTC), a clinical-stage biotechnology company focused on the development and commercialization of adeno-associat...

Applied Genetic Technologies ( NASDAQ: AGTC ) announced Tuesday it plans to initiate underwritten stock offering that will see the issue of its common shares and accompanying stock purchase warrants. The company intends to use the net proceeds for fund its ongoing Skylin...

GAINESVILLE, Fla. and CAMBRIDGE, Mass., July 12, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (“AGTC” or the “Company”) (Nasdaq: AGTC), a clinical-stage biotechnology company focused on the development and commercialization of adeno-associate...

GAINESVILLE, Fla., and CAMBRIDGE, Mass., July 07, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical-stage biotechnology company focused on the development of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and ...